The present invention relates to new thiadiazolidmediones of formula (I), or any pharmaceutically acceptable salt, solvate or prodrug thereof, and its use in the treatment of a disease in which glycogen synthase kinase 3 (GSK-3) is involved, particularly neurodegenerative diseases, inflammatory and autoimmune diseases and cardiovascular disorders. Additionally, there is provided a process for preparing such compounds, as well as pharmaceutical compositions comprising them.
本发明涉及公式(I)的新
噻二唑烷二酮,或其任何药学上可接受的盐、溶剂合物或前药,以及其在治疗涉及
糖原合成酶激酶3(GSK-3)的疾病中的用途,特别是神经退行性疾病、炎症性和自身免疫疾病以及心血管疾病。此外,还提供了制备这类化合物的方法,以及包含它们的药物组合物。